MiNK Therapeutics, Inc. (INKT) Financial Statements
Industry: Biological Products, (No Diagnostic Substances)
In fiscal 2025, MiNK Therapeutics reported revenue of $0. Net income was -$12.5M, or -$2.93 per diluted share. Operating activities generated -$5.9M of cash. At fiscal year end, MiNK Therapeutics held $14.2M in total assets against $28.5M in total liabilities, including $13.4M of cash and equivalents.
Open the full interactive MiNK Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
MiNK Therapeutics Key Stats
| Share Price | $10.23 |
|---|---|
| Market Cap | $51.4M |
| 52-Week Range | $8.56 – $14.98 |
| Shares Outstanding | 5.0 million (basic, 2026 Q2) |
MiNK Therapeutics Income Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| Operating Income | -$28.4M | -$30.9M | -$22.9M | -$11.3M | -$12.6M |
| Pre-Tax Income | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M |
| Net Income | -$30.2M | -$28.0M | -$22.5M | -$10.8M | -$12.5M |
| Diluted EPS | -$11.60 | -$8.30 | -$6.50 | -$2.86 | -$2.93 |
MiNK Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.9M | -$2.6M | -$2.7M | -$3.1M |
| Diluted EPS | -$0.65 | -$0.61 | -$0.57 | -$0.62 |
MiNK Therapeutics Balance Sheet
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash & Equivalents | — | $19.6M | $3.4M | $4.6M | $13.4M |
| Current Assets | $39.6M | $20.4M | $3.6M | $5.0M | $13.8M |
| Total Assets | $40.2M | $21.5M | $4.6M | $5.7M | $14.2M |
| Current Liabilities | $16.5M | $12.7M | $11.4M | $7.0M | $13.0M |
| Total Liabilities | $16.5M | $21.9M | $22.6M | $25.3M | $28.5M |
| Shareholders' Equity | $23.8M | -$401,303 | -$18.1M | -$19.6M | -$14.2M |
MiNK Therapeutics Cash Flow Statement
| FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|
| Cash From Operations | -$12.8M | -$18.9M | -$15.8M | -$9.6M | -$5.9M |
| Cash From Investing | -$248,983 | -$250,046 | -$73,561 | — | — |
| Cash From Financing | $49.3M | -$155,599 | -$407,173 | $10.8M | $14.7M |
| Free Cash Flow | -$13.1M | -$19.1M | -$15.8M | -$9.6M | — |
Figures from MiNK Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full MiNK Therapeutics financials page for every line item.
MiNK Therapeutics Company Profile
| Ticker | INKT |
|---|---|
| Exchange | Nasdaq |
| Industry | Biological Products, (No Diagnostic Substances) |
| Headquarters | New York, New York |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company, emerging growth company |
| SEC CIK | 0001840229 |
Frequently Asked Questions
What was MiNK Therapeutics' revenue in fiscal 2025?
MiNK Therapeutics (INKT) reported revenue of $0 for fiscal 2025.
What is MiNK Therapeutics' annual revenue history?
MiNK Therapeutics' annual revenue by fiscal year: 2021: $0; 2022: $0; 2023: $0; 2024: $0; 2025: $0.
What was MiNK Therapeutics' net income in fiscal 2025?
MiNK Therapeutics reported net income of -$12.5M for fiscal 2025.
What was MiNK Therapeutics' earnings per share (EPS) in fiscal 2025?
MiNK Therapeutics' diluted EPS was -$2.93 for fiscal 2025 (adjusted for any later stock splits).
What was MiNK Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), MiNK Therapeutics reported revenue of $0.
How many shares of MiNK Therapeutics are outstanding?
MiNK Therapeutics reported a weighted average of 5.0 million basic shares outstanding in 2026 Q2.
What is MiNK Therapeutics' market cap?
Based on its latest closing price, MiNK Therapeutics (INKT) has a market capitalization of about $51.4M.
When does MiNK Therapeutics' fiscal year end?
MiNK Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is MiNK Therapeutics headquartered?
MiNK Therapeutics lists its business address in New York, New York in its SEC filings.
MiNK Therapeutics Competitors & Similar Companies
See all 136 Biological Products, (No Diagnostic Substances) companies →